- Research article
- Open Access
- Open Peer Review
Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin
© Ravizza et al; licensee BioMed Central Ltd. 2004
- Received: 15 September 2004
- Accepted: 15 December 2004
- Published: 15 December 2004
Colon adenocarcinomas are refractory to a number of widely used anticancer agents. Multifactorial mechanisms have been implicated in this intrinsically resistant phenotype, including deregulation of cell death pathways. In this regard, the p53 protein has a well established role in the control of tumor cell response to DNA damaging agents; however, the relationship between p53-driven genes and drug sensitivity remains controversial. The present study investigates the role of the p53/p21 system in the response of human colon carcinoma cells to treatment with the cytotoxic agent doxorubicin (DOX) and the possibility to modify the therapeutic index of DOX by modulation of p53 and/or p21 protein levels.
The relationship between p53 and p21 protein levels and the cytotoxic effect of DOX was investigated, by MTT assay and western blot analysis, in HCT116 (p53-positive) and HT29 (p53-negative) colon cancer cells. We then assessed the effects of DOX in two isogenic cell lines derived from HCT116 by abrogating the expression and/or function of p53 and p21 (HCT116-E6 and HCT116 p21-/-, respectively). Finally, we evaluated the effect of pre-treatment with the piperidine nitroxide Tempol (TPL), an agent that was reported to induce p21 expression irrespective of p53 status, on the cytotoxicity of DOX in the four cell lines. Comparisons of IC50 values and apoptotic cell percentages were performed by ANOVA and Bonferroni's test for independent samples. C.I. calculations were performed by the combination Index method.
Our results indicate that, in the colon carcinoma cell lines tested, sensitivity to DOX is associated with p21 upregulation upon drug exposure, and DOX cytotoxicity is potentiated by pre-treatment with TPL, but only in those cell lines in which p21 can be upregulated.
p21 induction may significantly contribute to the response of colon adenocarcinomas cells to DOX treatment; and small molecules that can exploit p53-independent pathways for p21 induction, such as TPL, may find a place in chemotherapeutic protocols for the clinical management of colorectal cancer, where p53 function is often lost, due to genetic or epigenetic defects or to post-transcriptional inactivating mechanisms.
- HCT116 Cell
- Human Colon Carcinoma Cell
- HCT116 Cell Line
- Tumor Cell Response
Colorectal cancer is the second most common cause of cancer-related mortality in Western countries, with about 1 million new cases every year diagnosed world-wide and 500,000 patients dying from the disease . Of the patients, 30% have advanced disease at presentation, either locally or at distant sites; in this setting, chemotherapy remains the only viable therapeutic option. However, even this option is severely hindered by the inherent resistance of metastatic colon cancer to many currently used anticancer agents. A variety of mechanisms by which cancer cells resist chemotherapy have been described, including enhanced export of drugs from cancer cells and alterations in drug metabolism and/or in drug-target interactions . In addition, the response of cancer cells to genotoxic therapies may be critically impaired by defects in the response mechanisms to DNA damage  or in cell cycle regulatory pathways .
Over the past decade, induction of apoptosis has emerged as a major event in tumor cell response to cytotoxic agents (for a recent review see ). This view, although recently challenged by some Authors , has attracted considerable attention on deregulation of cell death pathways as a key determinant of drug resistance.
Two separable, although extensively cross-talking, pathways leading to apoptosis have been characterized [7, 8]. The extrinsic pathway is initiated by ligation of transmembrane receptors to activate membrane proximal "activator" caspases, which in turn cleave and activate downstream "effector" caspases. The intrinsic pathway requires disruption of the mitochondrial membrane and the release of mitochondrial proteins, two events that are regulated by the opposing actions of pro- and antiapoptotic Bcl-2 family members. "Intrinsic stresses", such as those produced by DNA-damaging agents, activate the intrinsic apoptotic pathway; the multifunctional transcription factor p53 is thought to be part of a "fast track" connection between nuclear DNA damage and the intrinsic pathway machinery . p53 regulates multiple responses to genotoxic stress by transcriptional activation or repression of a number of genes encoding proteins involved in cell cycle control (p21WAF1/Cip1), DNA repair (gadd45), and apoptosis (e.g. Bax, Bcl2 and survivin) . Mutations in p53 and in the p53 pathway can produce multidrug resistance in vitro and in vivo, and reintroduction of wildtype p53 into p53 null tumor cells can re-establish chemosensitivity . p53 status is not a universal predictor of treatment response, in part because not all drugs absolutely require p53 for their apoptotic function  and in some settings, p53 loss can enhance drug-induced apoptotic cell death . Still, loss of p53 function correlates with multidrug resistance in many tumor types  and the observation that this is a common defect in human tumors has spurred an active search for strategies aimed at directly activating cell death pathways downstream of p53. In this scenario, the role played by the cyclin-dependent kinase inhibitor p21 is particularly intriguing, as this protein can be activated by both p53-dependent and p53-independent mechanisms and can assume pro- or anti-apoptotic functions, depending on the cellular context (for a review see ).
Standard chemicals, including 4-hydroxy-2,2,6,6-tetramethylipiperidine-N-oxyl (Tempol, TPL) and cell culture reagents were purchased from Sigma-Aldrich srl. (Milan, Italy), unless otherwise indicated; doxorubicin (DOX) was kindly provided by Dr. A Suarato (Pfizer-Pharmacia, Milan, Italy).
The human colon carcinoma cell lines HCT116, HT29 (obtained from ATCC, Rockville, MD) and HCT116 p21-negative cells (HCT116 p21-/-), kindly provided by Dr B. Vogelstein (Johns Hopkins University, Baltimore, MD, USA), were maintained in DMEM medium supplemented with 10% FBS (Mascia Brunelli); the HCT116-E6 cell line, obtained from HCT116 cells by transfection with pCMVneo-E6 plasmid (provided by Dr B. Vogelstein) containing the HPV16-E6 human gene, was maintained in ISCOVE medium supplemented with 10% FBS and geneticin (500 μg/ml). All the cell lines were cultured at 37°C, in an atmosphere of 5% CO2 and 95% humidity.
The effects of DOX and/or TPL on cell growth were assessed by the MTT assay . Briefly, cells were seeded onto 96-well plates and allowed to grow for 24 h prior to treatment. Three different treatment schedules were used: a) 24 h medium, 1 h DOX (0.05 – 10 μM) followed by 72 h incubation in drug-free medium; b) 24 h TPL (0.05 – 10 mM) followed by 72 h incubation in drug-free medium; c) 24 h TPL followed by 1 h DOX and by 72 h incubation in drug-free medium. For combination experiments, the whole range of DOX concentrations (0.05 – 10 μM) was tested following pretreatment with fixed TPL concentrations, corresponding to the IC25 or IC50values obtained for each cell line according to schedule (b). At the end of the treatment period, 50 μl of MTT (2 mg/ml in PBS) were added to each well at 37°C for 3 h and the reduction of MTT by viable cells was measured colorimetrically at 570 nm, using a Universal Microplate Reader EL800 (Bio-Tek Instruments). IC25 and IC50 values (i.e. the concentrations yielding 75% and 50% cell survival fractions, respectively) were calculated according to the median effect equation and analysis of the interaction between DOX and TPL was performed as described by Chou & Talalay .
Transfection of HCT116 cells
Transfection of HCT116 cells with the pCMVneo-E6 plasmid was performed by electroporation as described by Yanez and Porter , using a Bio-Rad Gene Pulser unit at the following conditions: 280 V, 960 μF. 48 h post-transfection the cells were selected by adding 500 μg/ml of geneticin to the culture medium. The efficiency and stability of transfection were checked by Western blot analysis of whole cell lysates. Control cells were mock-transfected with the pCMVneo plasmid.
Preparation of cell extracts and immunoblotting
The expression of p53 and p21, before and after 1 h exposure to DOX (1.0 and 10 μM) followed by 23 h incubation in drug-free medium, or after 24 h exposure to TPL (1.0 and 2.5 mM), was evaluated by Western blot analysis of total protein extracts (lysis buffer: NP40 1%, leupeptin 10 μg/ml and aprotinin 10 μg/ml in TBS). Protein concentration in the cellular lysates was determined by the BCA assay (Pierce, Rockford, IL, USA). 15 μg of protein extract/lane were loaded onto 11% polyacrylamide gels and separated under denaturing conditions. Protein samples were then transferred onto nitrocellulose membrane and Western blot analysis was performed by standard techniques. using a mouse anti-p53 monoclonal antibody (DO-1; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and a rabbit anti-p21 polyclonal antibody (C-19; Santa Cruz Biotechnology). Proteins were visualized using peroxidase-conjugated anti-mouse and anti-rabbit secondary antibodies (Amersham Pharmacia Biotech) and the ECL Plus Western Blotting Detection Reagents (Amersham Pharmacia Biotech).
Densitometric analysis was performed using the Scion Image software (Scion Corporation, Frederick, MD).
Flow cytometric analysis of apoptotic cells
The presence of apoptotic cells in HCT116, HT29, HCT116-E6 and HCT116 p21 -/-, before and after 1 h exposure to DOX (1.0 and 10 μM) followed by 23 h incubation in drug-free medium, was evaluated by flow cytometric analysis, using a Becton Dickinson FACScalibur flow cytometer. Cells were detached by trypsinization, washed in phosphate-buffered saline (PBS) and fixed in ice-cold 70% ethanol for 20 min at -20°C. After an additional wash in PBS, DNA was stained with 50 mg/ml propidium iodide in PBS in the presence of RNAse A (30 U/ml) at 37°C for 30 minutes. 5 × 105 cell samples were analyzed and data were processed using the CellQuest software (Becton Dickinson). The percentage of apoptotic cells in each sample was determined based on the sub-G1 peaks detected in monoparametric histograms.
Comparisons of IC50 values and apoptotic cell percentages in the four different cell lines were performed by ANOVA and Bonferroni's test for independent samples. C.I. calculations an relative statistical analysis were performed as described by Chou and Talalay . According to this method, a combination index (C.I.) can be calculated from dose-response curves obtained following exposure to DOX and/or TPL as single agents and in combination. C.I. values approximating 1.0 indicate additive interactions between the two agents; C.I. < 1.0 indicate synergy and, conversely, C.I. > 1.0 indicate antagonism.
IC50values obtained after 1 h exposure to DOX followed by 72 h incubation in drug free medium (mean ± s.e.m. of 4–6 independent experiments).
0.38 ± 0.03
2.37 ± 0.13 *
0.732 ± 0.06 *
4.98 ± 0.32 *
Immune detection of p53 and p21
Evaluation of apoptotic cells by flow cytometric analysis
Effects of TPL on cell survival and p53/p21 levels
IC50values obtained after 24 h exposure to TPL followed by 72 h incubation in drug free medium. (mean ± s.e.m. of 4–6 independent experiments).
280.00 ± 39.21
560.00 ± 77.78
320.40 ± 50.03
665.63 ± 102.91
400.06 ± 60.00
837.3 ± 103.99
700.00 ± 99.14
1114.55 ± 182.2
Effects of TPL pretreatment on DOX-induced cytotoxicity
IC50values obtained after 24 h exposure to TPL followed by 1 h exposure to DOX and 72 h incubation in drug free medium (mean ± s.e.m. of 4–6 independent experiments).
+ TPL (IC25)
+ TPL (IC50)
0.38 ± 0.03
0.102 ± 0.04
0.053 ± 0.003
2.20 ± 0.11
1.06 ± 0.12
0.49 ± 0.015
0.77 ± 0.06
0.54 ± 0.6
0.24 ± 0.07
5.457 ± 0.16
4.98 ± 0.15
2.549 ± 0.21
Resistance of colorectal cancer to established treatment regimens remains a major concern in oncology; thus attempts at improving the survival of patients affected by this disease depend largely on strategies targeting tumor cell resistance, which cannot be rationally planned without a detailed knowledge of the mechanisms underlying this phenomenon. A current paradigm regarding cancer chemotherapy indicates disabling of the intrinsic apoptotic pathway as a key factor in the response of tumor cells to anticancer drugs [3, 5, 12]. Therefore, strategies aiming at re-establishing the cell's capability to activate a cell death program are an area of active research. The present study was performed in order to define the role of the p53/p21 pathway in the response of colorectal carcinoma cells to DOX, a cytotoxic agent that is typically devoid of effects in this tumor type. The results obtained in our cytotoxicity studies indicate that in the cell lines examined p53 status is not unequivocally related to the response to DOX: in fact, while p53-deficient cells (HT-29, HCT116-E6) are indeed less responsive than the p53/wt parental HCT116 cell line, the highest resistance index was obtained for HCT116 p21-/- cells, harboring two wildtype p53 alleles. As expected, treatment with DOX leads to p53 upregulation in the cell lines expressing wildtype p53; this effect has been thoroughly documented in colon cancer cells as well as in tumor cell lines derived from other tissues, and has been attributed to phosphorylation and subsequent stabilization of p53, possibly through activation of DNA-dependent protein kinase or ATM (ataxia-teleangectasia mutated) kinase (see e.g. [20–22]). In HCT116 cells, p21 expression parallels p53 activation; however, data obtained in HT29 and HCT116-E6 cells clearly indicate the existence of p53-independent pathways for p21 induction, that have been extensively characterized (for a review see ) and can be activated to variable extents (HCT116 E6 > HT29) upon exposure to DOX. Interestingly, the extent of the cytotoxic effects observed in the small panel of colon cell lines tested rather seems to parallel the cells' ability to upregulate p21 (HCT116 > HCT116-E6 > HT29 > HCT116 p21-/-). This result is somewhat unexpected: in fact, whereas the function of p21 in cell growth arrest following DNA damage has been established for a long time , the role played by this protein in the ultimate fate of tumor cells exposed to cytotoxic agents is far from clear-cut [14, 25]. In a number of studies, p21 has actually been reported to protect tumor cells against cell death induced by enforced p53 expression  or by low doses of cytotoxic agents [13, 27–30]. However, in other experimental settings, p53-dependent or -independent induction of p21 expression seems to be a prerequisite for apoptosis [31–34] and to sensitize tumor cells to the action of different agents [35–37]. The putative mechanisms by which p21 might actually induce apoptosis have recently been reviewed , but still await full elucidation.
Interestingly, the situation outlined by our results does not seem to conform to either view: in fact, while induction of p21 in p53-proficient and -deficient cell lines is associated with increased response to drug treatment, this was not accompanied by a parallel increase in apoptotic cells, as no significant differences in apoptosis were observed between HCT116 cells and the 14-fold resistant HCT-116 p21-/- cell line (figure 4). This suggests that modes of cell death other than apoptosis may operate in tumor cells following exposure to DOX, or, more generally, to DNA-damaging agents, a concept that is beginning to be proposed by a number of Authors [39, 40]; of note, recent experimental evidence indicates p21 as one of the major determinants of terminal growth arrest induced by cytotoxic agents [41–43]. Therefore, although issues related to terminal growth arrest and senescence have not been specifically addressed in the present study, the possibility that these phenomena might play a role linking cell death to the observed increases in p21 levels should not be disregarded.
The hypothesis that the cytotoxic response of the tumor cell lines tested in the present study may depend on p21 induction is further corroborated by data obtained following pre-treatment with the piperidine nitroxide TPL. The choice of this compound was dictated by previous findings indicating that TPL induces cell death in a number of tumor cell lines irrespective of their p53 status , and that it increases p21 levels in p53-null cells . The results of the present study show that TPL affects the four colon cell lines to similar extents, thus confirming that its growth inhibitory effect is independent of p53 function. HCT-116 p21-/- cells are actually slightly less responsive than the other cell lines [even though the difference does not attain statistical significance), which suggests the possibility that the effects of TPL are due in part to its ability to increase p21 levels. Interestingly, the nitroxide also induces p21 expression even in p53-deficient cell lines; this observation suggests that TPL can activate p53-independent pathways for p21 induction, as already noted following exposure of HT29 and HCT116 E6 cells to DOX. Moreover, activation of such pathways by TPL appears to sensitize tumor cells to the action of DOX: in fact, synergistic potentiation of DOX cytotoxicity is achieved by TPL in those cell lines where p21 expression can be induced, but only additive effects between TPL and DOX are observed in HCT116 p21-/-, where p21 expression is constitutively absent.
In summary, the results of the present study strongly suggest that 1) p21 induction may significantly contribute to the response of colon adenocarcinoma cells to DOX treatment; and 2) small molecules that can exploit p53-independent pathways for p21 induction, such as TPL, may find a place in chemotherapeutic protocols for the clinical management of colorectal cancer, where p53 function is often lost, due to genetic or epigenetic defects or to post-transcriptional inactivating mechanisms.
Supported by a grant from the Italian Ministry for Education, University and Research (MIUR), Projects with Relevant National Impact (PRIN), 2003 (to E.M.).
- Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. 2001, IARC CancerBase Lyon, IARCPress, 5:Google Scholar
- Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 2002, 53: 615-627. 10.1146/annurev.med.53.082901.103929.View ArticlePubMedGoogle Scholar
- Shah AM, Schwartz GK: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res. 2001, 7: 2168-2181.PubMedGoogle Scholar
- Ferreira CG, Epping M, Kruyt FA, Giaccone G: Apoptosis: target of cancer therapy. Clin Cancer Res. 2002, 8: 2024-2034.PubMedGoogle Scholar
- Brown JM, Wilson G: Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us?. Cancer Biol Ther. 2003, 2: 477-490.View ArticlePubMedGoogle Scholar
- Green DR: Apoptotic pathways: paper wraps stone blunts scissors. Cell. 2000, 102: 1-4. 10.1016/S0092-8674(00)00003-9.View ArticlePubMedGoogle Scholar
- Johnstone RW, Ruefli AA, Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002, 108: 153-164. 10.1016/S0092-8674(02)00625-6.View ArticlePubMedGoogle Scholar
- Wang X: The expanding role of mitochondria in apoptosis. Genes Dev. 2001, 15: 2922-2933.PubMedGoogle Scholar
- Lowe SW, Lin AW: Apoptosis in cancer. Carcinogenesis. 2000, 21: 485-495. 10.1093/carcin/21.3.485.View ArticlePubMedGoogle Scholar
- Vousden K, Lu X: Live or let die: the cell's response to p53. Nature Rev Cancer. 2002, 2: 594-604. 10.1038/nrc864.View ArticleGoogle Scholar
- Wallace-Brodeur RR, Lowe SW: Clinical implications of p53 mutations. Cell Mol Life Sci. 1999, 55: 64-75. 10.1007/s000180050270.View ArticlePubMedGoogle Scholar
- Herr I, Debatin MK: Cellular stress response and apoptosis in cancer therapy. Blood. 2001, 98: 2603-2614. 10.1182/blood.V98.9.2603.View ArticlePubMedGoogle Scholar
- Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999, 104: 263-269.View ArticlePubMedPubMed CentralGoogle Scholar
- Liu X, Bishop WR, Liu M: Differential effects of cell cycle regulatory protein p21WAF1/Cip1 on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updates. 2003, 6: 183-195. 10.1016/S1368-7646(03)00044-X.View ArticleGoogle Scholar
- Gariboldi MB, Lucchi S, Caserini C, Supino R, Oliva C, Monti E: Antiproliferative effect of the piperidine nitroxide TEMPOL on neoplastic and nonneoplastic mammalian cell lines. Free Rad Biol Med. 1998, 24: 913-923. 10.1016/S0891-5849(97)00372-9.View ArticlePubMedGoogle Scholar
- Gariboldi MB, Rimoldi V, Supino R, Favini E, Monti E: The nitroxide TEMPOL induces oxidative stress, p21 WAF1/CIP1, and cell death in HL60 cells. Free Rad Biol Med. 2000, 29: 633-641. 10.1016/S0891-5849(00)00347-6.View ArticlePubMedGoogle Scholar
- Supino R: MTT assays. In Methods in molecular biology: in vitro toxicity testing protocols. Edited by: O'Hare SM, Atterwill CK. 1998, Totowa, NJ: Humana Press, 43: 137-149.Google Scholar
- Chou T-C, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55. 10.1016/0065-2571(84)90007-4.View ArticlePubMedGoogle Scholar
- Yanez RJ, Porter AC: Influence of DNA delivery method on gene targeting frequencies in human cells. Somat Cell Mol Genet. 1999, 25: 27-31. 10.1023/B:SCAM.0000007137.28557.73.View ArticlePubMedGoogle Scholar
- Kaeser MD, Pebernard S, Iggo RD: Regulation of p53 stability and function in HCT116 colon cancer cells. J Biol Chem. 2004, 279: 7598-7605. 10.1074/jbc.M311732200.View ArticlePubMedGoogle Scholar
- Kurz EU, Douglas P, Lees-Miller SP: Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem. 2004, Oct 14.Google Scholar
- Take Y, Kumano M, Teraoka H, Nishimura S, Okuyama A: DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin. Biochem Biophys Res Commun. 1996, 221: 207-212. 10.1006/bbrc.1996.0575.View ArticlePubMedGoogle Scholar
- Gartel AL, Tyner AL: Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res. 1999, 246: 280-289. 10.1006/excr.1998.4319.View ArticlePubMedGoogle Scholar
- Dotto GP: p21(WAF1/Cip1): more than a break to the cell cycle?. Biochim Biophys Acta. 2000, 1471: M43-M56. 10.1016/S0304-419X(00)00019-6.PubMedGoogle Scholar
- Gartel AL, Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 2002, 1: 639-649.PubMedGoogle Scholar
- Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ: p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene. 1997, 14: 929-935. 10.1038/sj.onc.1200897.View ArticlePubMedGoogle Scholar
- Javelaud D, Besancon F: Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio. J Biol Chem. 2002, 277: 37949-37954. 10.1074/jbc.M204497200.View ArticlePubMedGoogle Scholar
- Martinez LA, Yang J, Vazquez ES, Rodriguez-Vargas M, del C, Olive M, Hsieh JT, Logothetis CJ, Navone NM: p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis. 2002, 23: 1289-1296. 10.1093/carcin/23.8.1289.View ArticlePubMedGoogle Scholar
- Mahyar-Roemer M, Roemer K: p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene. 2001, 20: 3387-3398. 10.1038/sj.onc.1204440.View ArticlePubMedGoogle Scholar
- Blagosklonny MV, Robey R, Bates S, Fojo T: Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest. 2000, 105: 533-539.View ArticlePubMedPubMed CentralGoogle Scholar
- Chopin V, Toillon RA, Jouy N, Le Bourhis X: p21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene. 2004, 23: 21-29. 10.1038/sj.onc.1207020.View ArticlePubMedGoogle Scholar
- Agrawal S, Agarwal ML, Chatterjee-Kishore M, Stark GR, Chisolm GM: Stat1-dependent, p53-independent expression of p21(waf1) modulates oxysterol-induced apoptosis. Mol Cell Biol. 2002, 22: 1981-1992. 10.1128/MCB.22.7.1981-1992.2002.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu Q, Kirschmeier P, Hockenberry T, Yang TY, Brassard DL, Wang L, McClanahan T, Black S, Rizzi G, Musco ML, Mirza A, Liu S: Transcriptional regulation during p21WAF1/CIP1-induced apoptosis in human ovarian cancer cells. J Biol Chem. 2002, 277: 36329-36337. 10.1074/jbc.M204962200.View ArticlePubMedGoogle Scholar
- Ahmad N, Adhami VM, Afaq F, Feyes DK, Mukhtar H: Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res. 2001, 7: 1466-73.PubMedGoogle Scholar
- Fulda S, Debatin KM: Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. 2004, 64: 337-346.View ArticlePubMedGoogle Scholar
- Satou M, Aizawa S, Hayakari M, Ookawa K, Tsuchida S: Enhanced sensitivity to cis-diamminedichloroplatinum(II) of a human carcinoma cell line with mutated p53 gene by cyclin-dependent kinase inhibitor p21(WAF1) expression. Cancer Sci. 2003, 94: 286-291.View ArticlePubMedGoogle Scholar
- Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD, Coffey RJ: Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nature Med. 1997, 3: 1233-1241. 10.1038/nm1197-1233.View ArticlePubMedGoogle Scholar
- Liu S, Bishop WR, Liu M: Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat. 2003, 6: 183-195. 10.1016/S1368-7646(03)00044-X.View ArticlePubMedGoogle Scholar
- Roninson IB: Tumor cell senescence in cancer treatment. Cancer Res. 2003, 63: 2705-2715.PubMedGoogle Scholar
- te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP: DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002, 62: 1876-1883.PubMedGoogle Scholar
- Chang BD, Swift ME, Shen M, Fang J, Broude EV, Roninson IB: Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci U S A. 2002, 99: 389-394. 10.1073/pnas.012602599.View ArticlePubMedGoogle Scholar
- Chang BD, Broude EV, Fang J, Kalinichenko TV, Abdryashitov R, Poole JC, Roninson IB: p21Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells. Oncogene. 2000, 19: 2165-2170. 10.1038/sj.onc.1203573.View ArticlePubMedGoogle Scholar
- Chang BD, Xuan Y, Broude EV, Zhu H, Schott B, Fang J, Roninson IB: Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene. 1999, 18: 4808-4818. 10.1038/sj.onc.1203078.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2407/4/92/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.